{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T01:37:10Z","timestamp":1789522630133,"version":"build-2803163510"},"reference-count":67,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T00:00:00Z","timestamp":1767052800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Genes"],"abstract":"<jats:p>Over the past several decades, rapid advances in molecular genomics have transformed our understanding of thyroid malignancies and are increasingly integrated into international clinical guidelines. Mutational profiles and epigenetic events are now recognized not only as diagnostic and prognostic tools but also as predictors of therapeutic response. Papillary, follicular, oncocytic, medullary, and anaplastic thyroid carcinomas harbor distinct early driver mutations, such as BRAFV600E, RAS, and fusion events (RET, NTRK, and ALK), that cooperate with secondary alterations (TERT promoter, TP53, PIK3CA, and CDKN2A\/B loss) to drive dedifferentiation, metastasis, and therapeutic resistance. Insights from The Cancer Genome Atlas (TCGA) and transcriptomic scoring systems (e.g., BRAF\u2013RAS score) now link genotype to tumor morphology, metastatic tropism, and radioactive iodine refractoriness. These molecular insights have been incorporated into updated risk stratification frameworks, preoperative surgical planning, and treatment algorithms, informing the selection of kinase inhibitors, redifferentiation strategies, and enrollment in genotype-directed clinical trials for radioiodine-refractory disease. This review synthesizes recent evidence connecting genomic alterations to clinical behavior and highlights their translation into evolving approaches for thyroid cancer management.<\/jats:p>","DOI":"10.3390\/genes17010036","type":"journal-article","created":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T15:05:01Z","timestamp":1767193501000},"page":"36","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Review of Genomic Drivers of Thyroid Cancer and Their Clinical Implications"],"prefix":"10.3390","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-7924-7624","authenticated-orcid":false,"given":"Sobrina","family":"Mohammed","sequence":"first","affiliation":[{"name":"Department of Endocrinology, Kansas City Veterans Affairs Medical Center, 4801 Linwood Blvd, Kansas City, MO 64128, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1735-8925","authenticated-orcid":false,"given":"Daniel","family":"Mettman","sequence":"additional","affiliation":[{"name":"Department of Pathology, Kansas City Veterans Affairs Medical Center, 4801 Linwood Blvd, Kansas City, MO 64128, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel Hugo","family":"Breier","sequence":"additional","affiliation":[{"name":"Department of Research, Kansas City Veterans Affairs Medical Center, 4801 Linwood Blvd, Kansas City, MO 64128, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vaishali","family":"Patel","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Kansas City Veterans Affairs Medical Center, 4801 Linwood Blvd, Kansas City, MO 64128, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana","family":"Garcia-Touza","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Kansas City Veterans Affairs Medical Center, 4801 Linwood Blvd, Kansas City, MO 64128, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,12,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"4981","DOI":"10.1158\/1078-0432.CCR-16-0384","article-title":"Progress in Endocrine Neoplasia","volume":"22","author":"Wells","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/0002-9343(77)90124-3","article-title":"Chronic myelocytic leukemia: Clonal origin in a stem cell common to the granulocyte, erythrocyte, platelet and monocyte\/macrophage","volume":"63","author":"Fialkow","year":"1977","journal-title":"Am. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/0092-8674(85)90115-1","article-title":"Activation of a novel human transforming gene, ret, by DNA rearrangement","volume":"42","author":"Takahashi","year":"1985","journal-title":"Cell"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/0092-8674(90)90659-3","article-title":"PTC is a novel rearranged form of the ret proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinomas","volume":"60","author":"Grieco","year":"1990","journal-title":"Cell"},{"key":"ref_5","first-page":"1457","article-title":"High frequency of activation of tyrosine kinase oncogenes in human papillary thyroid carcinoma","volume":"4","author":"Bongarzone","year":"1989","journal-title":"Oncogene"},{"key":"ref_6","first-page":"403","article-title":"Detection of activated ras oncogenes in human thyroid carcinomas","volume":"2","author":"Caillou","year":"1988","journal-title":"Oncogene"},{"key":"ref_7","first-page":"4459","article-title":"Activated ras oncogenes in human thyroid cancers","volume":"48","author":"Lemoine","year":"1988","journal-title":"Cancer Res."},{"key":"ref_8","first-page":"1369","article-title":"Unique association of p53 mutations with undifferentiated but not with differentiated carcinomas of the thyroid gland","volume":"52","author":"Ito","year":"1992","journal-title":"Cancer Res."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1111\/j.1349-7006.1992.tb02761.x","article-title":"p53 gene mutations associated with anaplastic transformation of human thyroid carcinomas","volume":"83","author":"Nakamura","year":"1992","journal-title":"Jpn. J. Cancer Res."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1172\/JCI116168","article-title":"High prevalence of mutations of the p53 gene in poorly differentiated human thyroid carcinomas","volume":"91","author":"Fagin","year":"1993","journal-title":"J. Clin. Investig."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1038\/363458a0","article-title":"Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A","volume":"363","author":"Mulligan","year":"1993","journal-title":"Nature"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1210\/jc.2005-1336","article-title":"PAX8-PPARgamma rearrangement is frequently detected in the follicular variant of papillary thyroid carcinoma","volume":"91","author":"Castro","year":"2006","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1126\/science.289.5483.1357","article-title":"PAX8-PPARgamma1 fusion oncogene in human thyroid carcinoma","volume":"289","author":"Kroll","year":"2000","journal-title":"Science"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"5399","DOI":"10.1210\/jc.2003-030838","article-title":"BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas","volume":"88","author":"Nikiforova","year":"2003","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1530\/ERC-13-0210","article-title":"Highly prevalent TERT promoter mutations in aggressive thyroid cancers","volume":"20","author":"Liu","year":"2013","journal-title":"Endocr. Relat. Cancer"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"E1562","DOI":"10.1210\/jc.2013-2383","article-title":"Frequent somatic TERT promoter mutations in thyroid cancer: Higher prevalence in advanced forms of the disease","volume":"98","author":"Landa","year":"2013","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1038\/ncomms3185","article-title":"Frequency of TERT promoter mutations in human cancers","volume":"4","author":"Vinagre","year":"2013","journal-title":"Nat. Commun."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2718","DOI":"10.1200\/JCO.2014.55.5094","article-title":"BRAF V600E and TERT promoter mutations cooperatively identify the most aggressive papillary thyroid cancer with highest recurrence","volume":"32","author":"Xing","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1001\/jamaoncol.2016.3288","article-title":"Mortality Risk Stratification by Combining BRAF V600E and TERT Promoter Mutations in Papillary Thyroid Cancer: Genetic Duet of BRAF and TERT Promoter Mutations in Thyroid Cancer Mortality","volume":"3","author":"Liu","year":"2017","journal-title":"JAMA Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1172\/JCI85271","article-title":"Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers","volume":"126","author":"Landa","year":"2016","journal-title":"J. Clin. Investig."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"4885","DOI":"10.1158\/0008-5472.CAN-09-0727","article-title":"Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1","volume":"69","author":"Ryder","year":"2009","journal-title":"Cancer Res."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"4256","DOI":"10.1158\/1078-0432.CCR-21-0874","article-title":"Oncogenic Mutations in PI3K\/AKT\/mTOR Pathway Effectors Associate with Worse Prognosis in BRAFV600E -Driven Papillary Thyroid Cancer Patients","volume":"27","author":"Pappa","year":"2021","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"ref_23","unstructured":"Cancer Genome Atlas Research Network (2014). Integrated genomic characterization of papillary thyroid carcinoma. Cell, 159, 676\u2013690."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1089\/thy.2023.0045","article-title":"Progress in Thyroid Cancer Genomics: A 40-Year Journey","volume":"33","author":"Fagin","year":"2023","journal-title":"Thyroid"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1089\/thy.2020.0826","article-title":"A Joint Statement from the American Thyroid Association, the European Association of Nuclear Medicine, the European Thyroid Association, the Society of Nuclear Medicine and Molecular Imaging on Current Diagnostic and Theranostic Approaches in the Management of Thyroid Cancer","volume":"31","author":"Gulec","year":"2021","journal-title":"Thyroid"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2759","DOI":"10.1210\/clinem\/dgad282","article-title":"Clinical use of Molecular Data in Thyroid Nodules and Cancer","volume":"108","author":"Alzahrani","year":"2023","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Corver, W.E., Ruano, D., Weijers, K., den Hartog, W.C.E., van Nieuwenhuizen, M.P., de Miranda, N., van Eijk, R., Middeldorp, A., Jordanova, E.S., and Oosting, J. (2012). Genome haploidisation with chromosome 7 retention in oncocytic follicular thyroid carcinoma. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0038287"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.ccell.2018.07.002","article-title":"Integrated Genomic Analysis of H\u00fcrthle Cell Cancer Reveals Oncogenic Drivers, Recurrent Mitochondrial Mutations, and Unique Chromosomal Landscapes","volume":"34","author":"Ganly","year":"2018","journal-title":"Cancer Cell"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.ccell.2018.06.013","article-title":"Widespread Chromosomal Losses and Mitochondrial DNA Alterations as Genetic Drivers in H\u00fcrthle Cell Carcinoma","volume":"34","author":"Gopal","year":"2018","journal-title":"Cancer Cell"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1001\/jamaoncol.2016.0386","article-title":"Nomenclature Revision for Encapsulated Follicular Variant of Papillary Thyroid Carcinoma: A Paradigm Shift to Reduce Overtreatment of Indolent Tumors","volume":"2","author":"Nikiforov","year":"2016","journal-title":"JAMA Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1177\/10507256251363120","article-title":"American Thyroid Association Management Guidelines for Adult Patients with Differentiated Thyroid Cancer","volume":"35","author":"Ringel","year":"2025","journal-title":"Thyroid"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"39","DOI":"10.18632\/genesandcancer.213","article-title":"Are molecular tests necessary to diagnose NIFTP?","volume":"12","author":"Kuchareczko","year":"2021","journal-title":"Genes Cancer"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1053\/j.semdp.2020.06.001","article-title":"Noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP): Diagnostic updates and molecular advances","volume":"37","author":"Chu","year":"2020","journal-title":"Semin. Diagn. Pathol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s00428-018-02512-6","article-title":"Molecular characterization of tumors meeting diagnostic criteria for the non-invasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP)","volume":"474","author":"Pool","year":"2019","journal-title":"Virchows Arch."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/modpathol.2016.157","article-title":"miRNA expression profiling of \u2018noninvasive follicular thyroid neoplasms with papillary-like nuclear features\u2019 compared with adenomas and infiltrative follicular variants of papillary thyroid carcinomas","volume":"30","author":"Borrelli","year":"2017","journal-title":"Mod. Pathol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"R259","DOI":"10.1530\/ERC-19-0048","article-title":"Noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP): A review for clinicians","volume":"26","author":"Rosario","year":"2019","journal-title":"Endocr. Relat. Cancer"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/359021a0","article-title":"Thyroid cancer after Chernobyl","volume":"359","author":"Kazakov","year":"1992","journal-title":"Nature"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"eabg2538","DOI":"10.1126\/science.abg2538","article-title":"Radiation-related genomic profile of papillary thyroid carcinoma after the Chernobyl accident","volume":"372","author":"Morton","year":"2021","journal-title":"Science"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/0092-8674(81)90021-0","article-title":"Identification and characterization of the familial adenomatous polyposis coli gene","volume":"66","author":"Groden","year":"1991","journal-title":"Cell"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1097\/GIM.0b013e3181ac9aea","article-title":"PTEN hamartoma tumor syndrome: An overview","volume":"11","author":"Hobert","year":"2009","journal-title":"Genet. Med."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"R31","DOI":"10.1172\/JCI10841","article-title":"Mutations in the protein kinase A R1\u03b1 regulatory subunit cause familial cardiac myxomas and Carney complex","volume":"106","author":"Casey","year":"2000","journal-title":"J. Clin. Investig."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1126\/science.272.5259.258","article-title":"Positional Cloning of the Werner\u2019s Syndrome Gene","volume":"272","author":"Yu","year":"1996","journal-title":"Science"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1002\/humu.21600","article-title":"Extending the phenotypes associated with DICER1 mutations","volume":"32","author":"Foulkes","year":"2011","journal-title":"Hum. Mutat."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.ecl.2025.03.016","article-title":"The Interaction Between Sex and Thyroid Cancer Development and Management","volume":"54","author":"Kitana","year":"2025","journal-title":"Endocrinol. Metab. Clin. N. Am."},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Achilla, C., Chorti, A., Papavramidis, T., Angelis, L., and Chatzikyriakidou, A. (2024). Genetic and Epigenetic Association of FOXP3 with Papillary Thyroid Cancer Predisposition. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25137161"},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Shobab, L., Zheng, H., Jensen, K., Mendonca-Torres, M.C., McCoy, M., Hoperia, V., Rosen, J., Wartofsky, L., Burman, K., and Vasko, V. (2024). Sex-Specific Expression of Histone Lysine Demethylases (KDMs) in Thyroid Cancer. Cancers, 16.","DOI":"10.3390\/cancers16071260"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"e180071","DOI":"10.1172\/JCI180071","article-title":"Epigenetic developmental mechanisms underlying sex differences in cancer","volume":"134","author":"Rubin","year":"2024","journal-title":"J. Clin. Investig."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"5678","DOI":"10.1038\/onc.2010.308","article-title":"Cross-talk between PI3K and estrogen in the mouse thyroid predisposes to the development of follicular carcinomas with a higher incidence in females","volume":"29","author":"Dima","year":"2010","journal-title":"Oncogene"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"T273","DOI":"10.1530\/ERC-14-0053","article-title":"Estrogen and its role in thyroid cancer","volume":"21","author":"Derwahl","year":"2014","journal-title":"Endocr. Relat. Cancer"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1002\/cncr.29934","article-title":"Prognostic effects of TERT promoter mutations are enhanced by coexistence with BRAF or RAS mutations and strengthen the risk prediction by the ATA or TNM staging system in differentiated thyroid cancer patients","volume":"122","author":"Song","year":"2016","journal-title":"Cancer"},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Ebina, A., Togashi, Y., Baba, S., Sato, Y., Sakata, S., Ishikawa, M., Mitani, H., Takeuchi, K., and Sugitani, I. (2020). TERT Promoter Mutation and Extent of Thyroidectomy in Patients with 1\u20134 cm Intrathyroidal Papillary Carcinoma. Cancers, 12.","DOI":"10.3390\/cancers12082115"},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Craig, S., Stretch, C., Farshidfar, F., Sheka, D., Alabi, N., Siddiqui, A., Kopciuk, K., Park, Y.J., Khalil, M., and Khan, F. (2023). A clinically useful and biologically informative genomic classifier for papillary thyroid cancer. Front. Endocrinol., 14.","DOI":"10.3389\/fendo.2023.1220617"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"bqad118","DOI":"10.1210\/endocr\/bqad118","article-title":"Mechanistic Insights of Thyroid Cancer Progression","volume":"164","author":"Landa","year":"2023","journal-title":"Endocrinology"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1002\/cncr.33421","article-title":"Risk assessment for distant metastasis in differentiated thyroid cancer using molecular profiling: A matched case-control study","volume":"127","author":"Yip","year":"2021","journal-title":"Cancer"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.surg.2022.05.048","article-title":"Association of comprehensive thyroid cancer molecular profiling with tumor phenotype and cancer-specific outcomes","volume":"173","author":"Liu","year":"2023","journal-title":"Surgery"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"108838","DOI":"10.1016\/j.surg.2024.06.066","article-title":"Tumor size and molecular risk group are associated with differentiated thyroid cancer recurrence","volume":"177","author":"Kurtom","year":"2025","journal-title":"Surgery"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.ejca.2019.10.017","article-title":"BRAF V600E status may facilitate decision-making on active surveillance of low-risk papillary thyroid microcarcinoma","volume":"124","author":"Kim","year":"2020","journal-title":"Eur. J. Cancer"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.surg.2021.03.056","article-title":"Presence of TERT \u00b1 BRAF V600E mutation is not a risk factor for the clinical management of patients with papillary thyroid microcarcinoma","volume":"170","author":"Lee","year":"2021","journal-title":"Surgery"},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Dettmer, M.S. (2025). The actual and future role of molecular tests in thyroid pathology. Virchows Arch.","DOI":"10.1007\/s00428-025-04334-9"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1056\/NEJMoa2309719","article-title":"Phase 3 Trial of Selpercatinib in Advanced RET -Mutant Medullary Thyroid Cancer","volume":"389","author":"Hadoux","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_61","first-page":"1184","article-title":"Dabrafenib Versus Dabrafenib + Trametinib in BRAF-Mutated Radioactive Iodine Refractory Differentiated Thyroid Cancer: Results of a Randomized, Phase 2, Open-Label Multicenter Trial","volume":"32","author":"Busaidy","year":"2022","journal-title":"Thyroid Off. J. Am. Thyroid Assoc."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"e2300052","DOI":"10.1200\/PO.23.00052","article-title":"D898_E901 RET Deletion Is Oncogenic, Responds to Selpercatinib, and Treatment Resistance Can Arise Via RET-Independent Mechanisms","volume":"7","author":"Porcelli","year":"2023","journal-title":"JCO Precis. Oncol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"e2300053","DOI":"10.1200\/PO.23.00053","article-title":"Patterns of Treatment Failure After Selective Rearranged During Transfection (RET) Inhibitors in Patients with Metastatic Medullary Thyroid Carcinoma","volume":"7","author":"Hadoux","year":"2023","journal-title":"JCO Precis. Oncol."},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Petranovi\u0107 Ov\u010dari\u010dek, P., Tuncel, M., Aghaee, A., Campenn\u00ec, A., and Giovanella, L. (2024). Redifferentiation Therapies in Thyroid Oncology: Molecular and Clinical Aspects. J. Clin. Med., 13.","DOI":"10.3390\/jcm13237021"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/S2213-8587(25)00064-6","article-title":"Redifferentiation therapy in unresectable or metastatic radioactive iodine refractory thyroid cancer: An International Thyroid Oncology Group statement","volume":"13","author":"Leboulleux","year":"2025","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Zhang, M., Xie, D., Hu, Y., Qin, G., and Xu, W. (Int. J. Cancer, 2025). Overdiagnosis of thyroid cancer in the United States: Improved estimates based on the SEER registries during 2000\u20132019, Int. J. Cancer, early view.","DOI":"10.1002\/ijc.70143"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1210\/clinem\/dgac646","article-title":"Current Controversies in Low-Risk Differentiated Thyroid Cancer: Reducing Overtreatment in an Era of Overdiagnosis","volume":"108","author":"Ullmann","year":"2023","journal-title":"J. Clin. Endocrinol. Metab."}],"container-title":["Genes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4425\/17\/1\/36\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T15:17:12Z","timestamp":1767194232000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4425\/17\/1\/36"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,30]]},"references-count":67,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1]]}},"alternative-id":["genes17010036"],"URL":"https:\/\/doi.org\/10.3390\/genes17010036","relation":{},"ISSN":["2073-4425"],"issn-type":[{"value":"2073-4425","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,30]]}}}